home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  BioSilico 2001: The Strategic Summit on In Silico Biology  
  November 14, 2001

Biotechnology

 
     
  Scientific American, The Plaza Hotel, Fifth Avenue at Central Park South, New York, NY 10019
February 19-20, 2002


This exclusive two-day conference will provide a one-of-a-kind forum to hear how the key players in the pharmaceutical, biotechnology, and computer industries plan to leverage the synthesis of their technologies to create the hottest new sector in the 21st century: the Application of Information Technology to Genomics.
-Presentations by "best-of-class" innovators
-Insights by strategists on how developments are likely to revolutionize multiple industries
-Expert opinions on how best to manage cross-industry innovation
-Ample time for formal and informal discussions that can generate new directions through networking and debate
 
 
Organized by: Stephen Edgington
Invited Speakers: Mark J. Levin, CEO, Millennium Pharmaceuticals *TBC
Tim Wells, Vice President Research, Head of Discovery, Serono
Jan Mous, Chief Scientific Officer, LION bioscience
Mark Murcko, VP & Chief Technology Officer, Vertex Pharmaceuticals
Bill Blake, VP, High Performance Technical Computing, Compaq
Manuel J. Glynias, President & CEO, NetGenics
Vijay Pillai, Director, Life Science Software Development Group, Oracle
Songnian Zhou, Founder, CEO and Chairman, Platform Computing
Srini Chari, Director, Solution Architecture and Strategy, IBM
Kenneth Carter, President and CEO, Avalon Pharmaceuticals
TBA, President & CEO, Myriad Proteomics
R. Mark Adams, Senior Director, Bioinformatics, Variagenics
William A. Haseltine, Chairman & CEO, Human Genome Sciences
Lex van der Pleog, Executive Director Metabolic Diseases, Merck & Co.
Gualberto Ruano, Chief Executive Officer, Genaissance Pharmaceuticals
Doros Platika, President and CEO, Curis
Aris Persidis, Managing Director, RheoGene
Jonathan M. Rothberg, Founder, Chairman and CEO, CuraGen
Klaus Lindpaintner, Director, Roche Genetics Hoffmann-La Roche
Richard T. Daly, President & CEO, Visible Genetics
Kari Stefansson, President, CEO, Secretary, deCODE genetics
Hugh Y. Rienhoff, Founder, Chairman and CEO, DNA Sciences
Lucia Quinn, Vice President, Developing Businesses, Quest Diagnostics
Douglas D. Lind, Principal, Morgan Stanley Dean Witter
Alan G. Walton, Chairman, Oxford Bioscience
William W. Crouse, Managing Director, Healthcare Ventures
Jeffrey Augen, Director, Life Sciences Strategy, IBM
Paul Herrling, Head of Research, Novartis Pharma AG*
Kenneth Sorensen, Managing Partner, Array Capital
Tim Rink, Chairman, Solexa
TBA: Five additional company presentations
 
Deadline for Abstracts: n/a
 
Registration: Register at www.bioedge.net
If you have any problems, please contact us at:
US: 800-737-1333
International: 402-996-9185
Fax: 973-429-8234
Email: biosilicoinfo@bioedge.net
E-mail: w.lau@noonanrusso.com
 
  Posted by:   Wendy Lau  
Host: 65.204.46.194
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2002 HUM-MOLGEN. All rights reserved. Liability and Copyright.